|
|
|
July 24, 2006
eyeonics reports continued robust
revenue traction for its innovative product, crystalens
crystalens, approved by the FDA in November
2003, is an intraocular lens which accommodates just like
a natural lens. By using the eye’s muscles to move
the lens forward and backwards, patients can focus through
a continuous range of vision including near, far, and
everywhere in between. Below, eyeonics reports continued robust revenue traction for its innovative product, crystalens.
----------------------------------
eyeonics, inc., the developer and manufacturer of the crystalens, the first and only FDA approved accommodating intraocular lens, today announced that revenues for the second quarter ended June 30, 2006 totaled $4.3 million, up 30 percent from revenues in the same period last year. Revenues for the first half of 2006 were $8.4 million, a 21 percent increase over the first half of 2005. At the same time, implants have grown more than 27 percent year-over-year. As previously announced, the crystalens has now been implanted in more than 50,000 patients worldwide.
"We are seeing more and more evidence that accommodating technology will become the lens of choice for surgeons and their patients in the premium channel market," said J. Andy Corley, Chairman and CEO of eyeonics. "As predicted, complications with multi-focal technology such as glare and halos, lack of intermediate vision, and loss of contrast sensitivity continue to surface."
Mr. Corley added, "Like our original crystalens, our second generation crystalens SE accommodating lens, introduced in September 2005, focuses vision at all distances much like the eye's natural lens and has been very well received by ophthalmologists and their patients. 'SE' reflects its square edge, and the crystalens SE implants are now growing at a faster rate than the first generation product with virtually no capsular issues."
Jay Pepose, MD, Director of the Pepose Vision Institute and Professor of Clinical Ophthalmology at Washington University School of Medicine in St. Louis, added, "crystalens has many advantages in that its mechanism of action closely resembles many aspects of natural accommodation. Most importantly, we do not hear complaints of disturbing night halos or waxy vision, which is more common with multi-focal lenses. We have had extremely high levels of patient satisfaction and the fewest complaints across the board with crystalens."
Kevin Waltz, MD, Director of Eye Surgeons of Indiana and Assistant Professor of Optometry at Indiana School of Optometry in Indianapolis agreed, adding, "The crystalens gives my patients the opportunity to see well at all distances with a minimal risk of glare and halos. It gives the patient and surgeon options that no other lens is able to deliver."
Back to News
|
|
| |
